Ethyl eicosapentaenoic acid/niacin - Amarin
Latest Information Update: 23 Apr 2011
At a glance
- Originator Amarin Corporation
- Mechanism of Action GPR109A receptor agonists; Phospholipase A2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hyperlipidaemia
Most Recent Events
- 29 Nov 2007 Phase-I clinical trials in Hyperlipidaemia in United Kingdom (PO)